What is the 13F Pro Quality Score for XTNT?

13F Pro ranks Xtant Medical Holdings, Inc. (XTNT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XTNT's current score at https://13fpro.ai/research/XTNT (free sign-up required for the full ranking).

Where does 13F Pro source XTNT data?

All Xtant Medical Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Xtant Medical Holdings, Inc. files with the SEC under CIK 1453593. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XTNT in?

Xtant Medical Holdings, Inc. (XTNT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XTNT research updated on 13F Pro?

XTNT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xtant Medical Holdings, Inc.(XTNT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1453593 XTNT stock profile & AI dashboard →

13F Pro Quality Score

52.2/100

Rank #1,354 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

76.4/100

Profitability

59.2/100

Balance Sheet

51.2/100

Earnings Quality

90.6/100

Free Cash Flow

41.7/100

Institutional Flow

33.0/100

Revenue Scale

19.6/100

Dilution Risk

40.0/100

XTNT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Xtant Medical Holdings, Inc. (XTNT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XTNT at 52.2/100 on a 32-signal composite quality model, placing it at rank #1,354 of 2,879 stocks — the top half of the AI-ranked universe. XTNT scores in the top quartile across earnings quality (90.6), revenue growth (76.4). Areas of concern include revenue scale (19.6) and institutional flow (33.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 40.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Xtant Medical Holdings, Inc. reports quarterly revenue of $20.9M, net income of $-3.1M, free cash flow of $-2.3M. Top institutional holders of XTNT by reported 13-F value include Nantahala Capital Management,, AWM Investment Company,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XTNT trades on the NYSE exchange and files with the SEC under CIK 1453593. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XTNT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xtant Medical Holdings, Inc. directly from SEC EDGAR.

✦

Fun facts about Xtant Medical Holdings, Inc.

Quirks, history, and lore behind XTNT — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap healthcare company headquartered in Montana · operates in the biologics and regenerative medicine space · listed on NYSE American.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is a micro-cap player, not a titan, but it serves a highly specialized surgical market.
3
The History
The company was built through acquisitions and restructuring in the 2010s, stitching together expertise in orthobiologics to serve spine and orthopedic surgeons.
4
The Secret
Its core products come from donated human tissue — processed and shaped into grafts that help bones fuse and heal after surgery. Nature, engineered.
5
The Lore
Based in Billings, Montana — not exactly the biotech zip code you'd expect — it supplies spine surgeons across the country with allografts and synthetic bone void fillers.
6
The Giveaway
Its ticker is literally XTNT — fitting for a company whose whole business is helping your skeletal system knit itself back together, one bone graft at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$20.9M

Net Income

Q1 2026

$-3.1M

Free Cash Flow

Q1 2026

$-2.3M

D/E Ratio

Q1 2026

0.24

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+14.2% YoY

$133.9MFY 2025

FY21 $55.3MFY22 $58.0MFY24 $117.3MFY25 $133.9M

Net Income

+130.2% YoY

$5.0MFY 2025

FY21 $-4.8MFY22 $-8.5MFY24 $-16.4MFY25 $5.0M

Operating Income

+160.3% YoY

$7.3MFY 2025

FY21 $-3.9MFY22 $-6.8MFY24 $-12.1MFY25 $7.3M

EPS (Diluted)

+125.0% YoY

$0.03FY 2025

FY21 $-0.06FY22 $-0.09FY24 $-0.12FY25 $0.03

Total Assets

+0.3% YoY

$94.1MFY 2025

FY21 $54.7MFY22 $60.2MFY24 $93.8MFY25 $94.1M

Total Debt

-34.1% YoY

$14.5MFY 2025

FY21 $11.8MFY22 $12.0MFY24 $22.0MFY25 $14.5M

Op. Cash Flow

+205.5% YoY

$12.5MFY 2025

FY21 $439.0KFY22 $-5.3MFY24 $-11.9MFY25 $12.5M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$133.9M +14.2%	$117.3M +102.3%	$58.0M +4.9%	$55.3M +3.6%	$53.3M -26.1%	$72.2M
Net Income	$5.0M +130.2%	$-16.4M -93.9%	$-8.5M -75.0%	$-4.8M +31.0%	$-7.0M +90.0%	$-70.1M
Operating Income	$7.3M +160.3%	$-12.1M -78.7%	$-6.8M -75.3%	$-3.9M -413.2%	$-751.0K +98.7%	$-60.1M
EPS (Diluted)	$0.03 +125.0%	$-0.12 -33.3%	$-0.09 -50.0%	$-0.06 +76.0%	$-0.25 +74.9%	$-0.99
Total Assets	$94.1M +0.3%	$93.8M +55.8%	$60.2M +10.1%	$54.7M +31.9%	$41.5M -10.7%	$46.4M
Total Debt	$14.5M -34.1%	$22.0M +83.3%	$12.0M +2.0%	$11.8M -29.8%	$16.8M -78.4%	$77.9M
Operating Cash Flow	$12.5M +205.5%	$-11.9M -122.7%	$-5.3M -1316.6%	$439.0K +160.1%	$-731.0K -160.3%	$1.2M

AI Insight: XTNT Financial Trends

Sharp revenue collapse in Q1 2026 to $21M reverses nine quarters of growth and profitability gains, though debt reduction continues.

• Revenue peaked at $35M in Q2 2025, then declined to $21M in Q1 2026—a 40% sequential drop marking the weakest quarter since Q3 2024.

• Operating income swung from +$3M in Q3 2025 to -$3M in Q1 2026, erasing six quarters of profitability momentum.

• Total debt fell from $22M in Q2 2024 to $12M in Q1 2026; equity stable near $49–51M range since Q3 2025.

⚠ Operating cash flow has swung negative (-$2M in Q1 2026) after four consecutive positive quarters; sustainability unclear.

⚠ Net income returned to loss (-$3M) in Q1 2026 after profitability in Q2–Q3 2025; root cause (demand, pricing, costs) requires clarification.

AI Insight: XTNT Ratio Trends

Xtant swung from TTM profitability back to sharp Q1 2026 losses across all return metrics, erasing a year of margin recovery.

• Operating margin collapsed to -14.0% in Q1 2026 from +7.6% in Q3 2025, lowest since Q3 2024's -13.5%.

• ROIC turned negative at -19.4% in Q1 2026 versus +26.1% in Q2 2025, a 45.5pp swing in 9 months.

• Net profit margin fell to -14.8% in Q1 2026 from +10.0% in Q2 2025; TTM NPM of 1.5% masks severe current-quarter deterioration.

⚠ Q1 2026 represents a reversal of Q2–Q3 2025 momentum; assess whether seasonal, one-time charge, or structural.

⚠ Leverage improved to 0.24 D/E (lowest since TTM), but profitability deterioration limits refinancing flexibility.

Get alerted when XTNT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xtant Medical Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XTNT

Nantahala Capital Management, LLC
$38.2M68,394,000 sh
AWM Investment Company, Inc.
$3.3M5,976,910 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.1M2,014,603 sh
RENAISSANCE TECHNOLOGIES LLC
$551.0K987,410 sh
GEODE CAPITAL MANAGEMENT, LLC
$295.4K529,214 sh
Crescent Grove Advisors, LLC
$229.9K412,024 sh
Hillsdale Investment Management Inc.
$202.1K362,200 sh
NANO CAP NEW MILLENNIUM GROWTH FUND L P
$195.3K350,000 sh
VANGUARD FIDUCIARY TRUST CO
$144.0K257,988 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$91.6K164,100 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$38.2M	68,394,000
AWM Investment Company, Inc.	$3.3M	5,976,910
VANGUARD CAPITAL MANAGEMENT LLC	$1.1M	2,014,603
RENAISSANCE TECHNOLOGIES LLC	$551.0K	987,410
GEODE CAPITAL MANAGEMENT, LLC	$295.4K	529,214
Crescent Grove Advisors, LLC	$229.9K	412,024
Hillsdale Investment Management Inc.	$202.1K	362,200
NANO CAP NEW MILLENNIUM GROWTH FUND L P	$195.3K	350,000
VANGUARD FIDUCIARY TRUST CO	$144.0K	257,988
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$91.6K	164,100

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XTNT on your watchlist

Track score changes the day Xtant Medical Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XTNT a good stock to buy?

13F Pro's AI-powered analysis of Xtant Medical Holdings, Inc. (XTNT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XTNT are available on the XTNT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XTNT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XTNT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xtant Medical Holdings, Inc.'s investment landscape.